PT  - JOURNAL ARTICLE
AU  - XUE MENG
AU  - FUMIHIKO MATSUMOTO
AU  - TAISUKE MORI
AU  - NAMI MIURA
AU  - YOSHINORI INO
AU  - KAORU ONIDANI
AU  - KENYA KOBAYASHI
AU  - YUSUKE MATSUZAKI
AU  - SEIICHI YOSHIMOTO
AU  - KATSUHISA IKEDA
AU  - KAZUFUMI HONDA
TI  - BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma
AID  - 10.21873/anticanres.14867
DP  - 2021 Feb 01
TA  - Anticancer Research
PG  - 1089--1099
VI  - 41
IP  - 2
4099  - http://ar.iiarjournals.org/content/41/2/1089.short
4100  - http://ar.iiarjournals.org/content/41/2/1089.full
SO  - Anticancer Res2021 Feb 01; 41
AB  - Background/Aim: Prognosis plays a vital role in head and neck squamous cell carcinoma (HNSCC) patient management and decision-making. This study aimed to identify the role of BP180 as a prognostic factor in HNSCC. Patients and Methods: Protein expression of bullous pemphigoid antigen II (BP180) was verified by immunohistochemistry (IHC) in a tissue microarray study of 202 cases. Results: IHC analysis revealed that protein expression of BP180 among HNSCC patients differed significantly in the presence and absence of neural invasion, and according to T status in laryngeal and pharyngeal cancer subgroups. Overall survival and multivariate analysis showed that positive BP180-IHC and advanced clinical stage were significant independent positive predictors of mortality in HNSCC patients. In addition, in the oral cancer subgroup, independent positive predictors were positive BP180-IHC, advanced N status and neural invasion. In laryngeal and pharyngeal cancer subgroups, predictors were positive BP180-IHC and advanced clinical stage. Conclusion: BP180 is a prognostic factor in head and neck squamous cell carcinoma.